Article: PERSONAL TIES HELP QUEENSBURY.(Business)

QUEENSBURY -- Manhattan-based Delcath Systems Inc. said Thursday it will establish a manufacturing, distribution, research and development facility in Queensbury as it prepares to produce its new medical device for delivering drugs to liver tumors.

The device, called a Percutaneous Hepatic Perfusion System, currently is in Phase III tests for delivering melphalan to the liver. It delivers higher doses of anti-cancer drugs while minimizing the amount of drugs that get into the rest of the patient's body, according to Delcath.

Delcath's CEO and president is a familiar name in Queensbury. He is Eamonn Hobbs, who previously headed Queensbury-based medical ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!